Compare Kodiak Gas Services Inc. Common Stock (KGS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kodiak Gas Services Inc. Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? Kodiak Gas Services Inc. Common Stock trades at $49.71 (market cap $5.06B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Kodiak Gas Services Inc. Common Stock and Travere Therapeutics Inc. Common Stock are close in size by market cap, and Kodiak Gas Services Inc. Common Stock pays a 3.91% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kodiak Gas Services Inc. Common Stock for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| KGS | TVTX | |
|---|---|---|
Market Cap | $5.06B | $5.02B |
Volume | 3,045,554 | 2,060,842 |
Sector | Energy | Health |
52-Week High | $76.27 | $67.52 |
52-Week Low | $32.95 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $7.74B | $5.15B |
Dividend Yield | 3.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KGS trades at $52.00, down 0.93% on the day, with technical indicators showing a bearish trend. The company reported Q2 2026 revenue growth but missed earnings expectations for three consecutive quarters. Recent developments include a significant power supply agreement for West Texas data centers, positioning KGS for future growth in distributed power generation.
Despite recent earnings misses, analyst consensus remains strongly bullish with a $80.38 price target representing 55% upside potential. Key risks include execution challenges in expanding power capacity and continued earnings volatility. The company's strategic pivot toward data center power services offers substantial growth opportunity if successfully executed.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kodiak Gas Services Inc. Common Stock
Kodiak Gas Services, Inc. is a Texas-based provider of large-horsepower contract natural gas compression services, operating a fleet of roughly 4.5 million revenue-generating horsepower for oil and gas producers and midstream companies across major US production basins, including the Permian, Eagle Ford, and DJ Basin.
Read more on KGS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
